Jambrovics, K.; Uray, I.P.; Keillor, J.W.; Fésüs, L.; Balajthy, Z.
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers 2020, 12, 648.
https://doi.org/10.3390/cancers12030648
AMA Style
Jambrovics K, Uray IP, Keillor JW, Fésüs L, Balajthy Z.
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers. 2020; 12(3):648.
https://doi.org/10.3390/cancers12030648
Chicago/Turabian Style
Jambrovics, Károly, Iván P. Uray, Jeffrey W. Keillor, László Fésüs, and Zoltán Balajthy.
2020. "Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2" Cancers 12, no. 3: 648.
https://doi.org/10.3390/cancers12030648
APA Style
Jambrovics, K., Uray, I. P., Keillor, J. W., Fésüs, L., & Balajthy, Z.
(2020). Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. Cancers, 12(3), 648.
https://doi.org/10.3390/cancers12030648